Cellular Ageing and Senescence in Dogs: The Impact of Natural Senolytic Compounds

Senolytics – Key to Slowing Ageing and Senescence in Dogs?

Summary

This comprehensive review examines the emerging field of cellular senescence in dogs and the potential of natural senolytic compounds to improve healthspan and quality of life in ageing canines. Cellular senescence—a state where cells cease dividing but remain metabolically active whilst secreting harmful inflammatory factors—has been identified as a key driver of age-related decline in dogs, contributing to cognitive dysfunction, cardiovascular disease, and reduced mobility.

Recent groundbreaking research, including the first randomised controlled trial of senolytic compounds in dogs, demonstrates that natural products such as quercetin, fisetin, curcumin, and oleuropein can selectively target senescent cells or reduce their harmful secretions. The landmark 2024 study showed that 88.9% of dogs receiving a senolytic combination demonstrated cognitive improvement compared to 60% receiving placebo, with no significant adverse effects.

This article synthesises current research on cellular senescence mechanisms in dogs, identifies key natural senolytic compounds and their comprehensive food sources, examines clinical evidence, and provides practical guidance for dog owners and veterinary professionals. The evidence suggests that natural senolytic interventions represent a promising, safe approach to promoting healthy ageing in companion dogs, with potential applications extending beyond cognitive function to cardiovascular health, immune function, and overall vitality.

Key Takeaways

• Cellular senescence is a major driver of ageing in dogs, affecting cognitive function, cardiovascular health, immune response, and physical mobility through the accumulation of damaged cells that secrete harmful inflammatory factors.
• Natural senolytic compounds have demonstrated clinical efficacy, with the first randomised controlled trial showing significant cognitive improvements in 88.9% of treated senior dogs compared to 60% receiving placebo.
• Multiple natural compounds show promise, including quercetin, fisetin, curcumin, oleuropein, resveratrol, and cardiac glycosides, each targeting different aspects of cellular senescence through distinct mechanisms.
• Safety profiles are favourable for natural senolytic compounds compared to synthetic alternatives, with intermittent dosing protocols showing sustained benefits and reduced risk of adverse effects.
• Comprehensive dietary sources exist for senolytic compounds, ranging from common fruits and vegetables to specialised herbs and botanicals, enabling both supplement-based and food-based approaches.
• Mechanisms of action are well-characterised, involving targeting of anti-apoptotic pathways, reduction of inflammatory secretions, enhancement of cellular cleanup mechanisms, and improvement of mitochondrial function.
• Individual variation exists in treatment response, necessitating personalised approaches based on age, breed, health status, and specific senescence markers.
• Research is rapidly advancing, with new compounds being identified and mechanisms better understood, suggesting continued improvements in treatment protocols and outcomes.

Table of Contents

Introduction

What is Senescence and Cellular Ageing in Dogs

• Definition of cellular senescence
• The ageing process in canines
• Hallmarks of ageing in dogs
• Types of senescent cells in dogs

Symptoms of Senescence and Cellular Ageing in Dogs

• Cognitive decline and dysfunction
• Cardiovascular manifestations
• Physical and mobility changes
• Immune system alterations
• Metabolic disruptions

Natural Senolytic Compounds: The Science Behind Cellular Renewal

• Understanding senolytics vs senomorphics
• Mechanisms of action
• Clinical evidence in dogs
• Advanced research methods

Key Senolytic Compounds Identified Through Research

• Quercetin and dasatinib combination
• Fisetin
• Curcumin
• Oleuropein and hydroxytyrosol
• Resveratrol
• Cardiac glycosides
• Kaempferol and other flavonoids
• Emerging compounds

Comprehensive Sources of Natural Senolytic Compounds

• Quercetin sources
• Fisetin sources
• Resveratrol sources
• Curcumin sources
• Oleuropein sources
• Other compound sources
• Preparation and bioavailability considerations

Mechanisms of Impact on Ageing and Senescence

• Cellular pathways targeted
• Cell-type specific mechanisms
• Mitochondrial function enhancement
• Inflammation reduction
• DNA repair and protection

Clinical Evidence and Research Findings

• Dog-specific studies
• Cardiovascular research applications
• Biomarkers and outcomes
• Safety considerations

Practical Applications and Implementation

• Dosing considerations
• Combination therapies
• Monitoring protocols
• Integration with veterinary care

Frequently Asked Questions (FAQ)

Future Directions and Research

Conclusion

References

Introduction

As veterinary medicine advances and our understanding of the ageing process deepens, researchers have identified cellular senescence as a fundamental driver of age-related decline in companion animals. Dogs, sharing remarkably similar ageing patterns with humans due to their common environment and lifestyle factors, serve as invaluable models for understanding how senescent cells contribute to cognitive decline, cardiovascular disease, and overall healthspan reduction.

The field of geroscience has experienced a revolutionary breakthrough with the identification of senolytic compounds—natural and synthetic substances capable of selectively targeting senescent cells for elimination or neutralising their harmful effects. Recent clinical evidence, including the first randomised controlled trial demonstrating cognitive improvements in senior dogs treated with senolytic combinations, validates years of preclinical research and opens new possibilities for enhancing quality of life in ageing canines.

This comprehensive review examines the current state of knowledge regarding cellular senescence in dogs, the mechanisms by which natural senolytic compounds exert their effects, and the practical implications for veterinary practice and dog ownership. By understanding how compounds found in everyday foods and botanicals can target the fundamental processes of ageing, we can develop evidence-based approaches to promoting healthy longevity in our canine companions.

What is Senescence and Cellular Ageing in Dogs

Definition of Cellular Senescence

Cellular senescence represents a critical biological process characterised by the permanent arrest of cell division whilst maintaining metabolic activity and resistance to programmed cell death. This state emerges as a response to various cellular stressors and serves as both a protective mechanism against cancer development and, paradoxically, a driver of ageing and age-related diseases.

The senescent phenotype encompasses several key features:

Cell cycle arrest: Senescent cells become permanently unable to divide, typically mediated through the activation of tumour suppressor pathways involving p53/p21 and p16INK4A/pRB signalling cascades.

Resistance to apoptosis: These cells develop enhanced survival mechanisms, often through upregulation of anti-apoptotic proteins from the BCL-2 family, allowing them to persist despite extensive cellular damage.

Senescence-Associated Secretory Phenotype (SASP): Perhaps most significantly, senescent cells secrete a complex mixture of inflammatory cytokines, chemokines, growth factors, and matrix-degrading enzymes that can profoundly affect surrounding tissues and promote age-related pathology.

Morphological changes: Senescent cells typically exhibit enlarged, flattened morphology with increased granularity and altered nuclear architecture.

The Ageing Process in Canines

Dogs experience ageing through mechanisms remarkably parallel to humans, making them exceptional translational models for understanding senescence. The accumulation of senescent cells in dogs follows predictable patterns influenced by:

Genetic factors: Breed-specific longevity genes and susceptibility to particular age-related conditions influence the rate and pattern of senescent cell accumulation.

Environmental stressors: Shared environmental exposures with humans, including pollution, UV radiation, and dietary factors, contribute to cellular damage and senescence induction.

Lifestyle factors: Activity levels, stress, diet quality, and social environment all influence the rate of cellular ageing in companion dogs.

Size and breed effects: Larger dog breeds typically experience accelerated ageing and earlier senescent cell accumulation compared to smaller breeds, correlating with shorter lifespans and earlier onset of age-related diseases.

Hallmarks of Ageing in Dogs

Research has identified twelve molecular hallmarks of ageing that manifest in dogs:

1. Genomic instability – Progressive accumulation of DNA damage from oxidative stress, environmental toxins, and replication errors
2. Telomere attrition – Shortening of protective chromosome caps with each cell division
3. Epigenetic alterations – Changes in gene expression patterns without DNA sequence changes
4. Loss of proteostasis – Impaired protein folding, degradation, and quality control mechanisms
5. Disabled macroautophagy – Reduced cellular cleanup and recycling processes
6. Deregulated nutrient sensing – Altered responses to nutritional signals and metabolic cues
7. Mitochondrial dysfunction – Impaired cellular energy production and increased oxidative stress
8. Cellular senescence – Accumulation of growth-arrested, inflammatory cells
9. Stem cell exhaustion – Reduced regenerative capacity of tissue-specific stem cell pools
10. Altered intercellular communication – Disrupted cell-to-cell signalling and coordination
11. Chronic inflammation – Persistent low-grade inflammatory state
12. Dysbiosis – Altered gut microbiome composition and function

Types of Senescent Cells in Dogs

Different cell types in dogs exhibit senescence with varying characteristics and impacts:

Endothelial cells: Line blood vessels and become senescent due to haemodynamic stress, oxidative damage, and inflammatory stimuli. Senescent endothelial cells lose their ability to produce nitric oxide effectively, leading to impaired vasodilation and increased thrombosis risk.

Vascular smooth muscle cells (VSMCs): These cells regulate blood vessel tone and when senescent, contribute to arterial stiffening, plaque instability, and vascular calcification through altered protein secretion and matrix remodelling.

Immune cells: T cells, macrophages, and other immune cells can become senescent, leading to immunosenescence characterised by reduced pathogen resistance, increased autoimmunity, and chronic inflammation.

Cardiomyocytes: Heart muscle cells accumulate senescence markers with age, contributing to cardiac dysfunction, fibrosis, and reduced regenerative capacity following injury.

Neural cells: Brain cells, including neurons and glial cells, can become senescent, contributing to cognitive decline, neuroinflammation, and neurodegenerative processes.

Skeletal muscle cells: Senescence in muscle tissue contributes to sarcopenia, reduced strength, and impaired mobility in ageing dogs.

Symptoms of Senescence and Cellular Ageing in Dogs

Cognitive Decline and Dysfunction

Cognitive changes represent the most extensively studied manifestation of cellular senescence in dogs, with Canine Cognitive Dysfunction Syndrome (CCDS) serving as the canine equivalent of human dementia.

Prevalence and progression: Studies indicate that 28% of dogs aged 11-12 years show signs of mild cognitive impairment, increasing dramatically to 68% in dogs over 16 years. The condition progresses through predictable stages from mild forgetfulness to severe dysfunction.

Specific manifestations include:

• Spatial disorientation: Dogs may become lost in familiar environments, fail to recognise their home, or appear confused about the location of doors, food bowls, or sleeping areas
• Memory impairment: Difficulty remembering learned commands, familiar people (including family members), or established routines
• Altered sleep-wake cycles: Increased nighttime restlessness, excessive daytime sleeping, or complete reversal of normal activity patterns
• Social withdrawal: Reduced interaction with family members, other pets, or previously enjoyed activities
• House soiling: Loss of house training despite maintained physical ability to control elimination
• Increased anxiety and confusion: Enhanced startle responses, increased vocalisation, or apparent distress in previously comfortable situations
• Compulsive behaviours: Repetitive pacing, excessive licking, or other stereotypical behaviours

Neurobiological basis: Senescent brain cells, particularly microglia and astrocytes, secrete inflammatory factors that damage neurons and disrupt normal brain function. The accumulation of senescent cells in the hippocampus (memory centre) and prefrontal cortex (executive function) correlates with cognitive decline severity.

Cardiovascular Manifestations

Recent research has identified cellular senescence as a major contributor to cardiovascular ageing in dogs, affecting multiple cardiac and vascular systems.

Endothelial dysfunction: Senescent endothelial cells lining blood vessels exhibit:

• Reduced nitric oxide production, leading to impaired vasodilation
• Increased expression of adhesion molecules promoting inflammation
• Enhanced thrombosis risk due to altered coagulation factor expression
• Compromised barrier function allowing increased vascular permeability

Vascular smooth muscle changes: Senescent VSMCs contribute to:

• Arterial stiffening through altered collagen and elastin production
• Atherosclerotic plaque formation and instability
• Vascular calcification through osteoblast-like transformation
• Impaired vascular tone regulation

Cardiac manifestations:

• Reduced cardiac output and exercise tolerance
• Increased susceptibility to arrhythmias
• Progressive fibrosis and stiffening of heart muscle
• Impaired response to cardiac stress or injury

Clinical presentations:

• Exercise intolerance and reduced activity levels
• Increased respiratory rate during minimal exertion
• Coughing, particularly at night or during activity
• Pale or blue-tinged gums indicating poor circulation
• Irregular heartbeat or heart murmurs

Physical and Mobility Changes

Senescent cells in musculoskeletal tissues contribute to characteristic physical changes of ageing:

Sarcopenia: Progressive loss of skeletal muscle mass and strength due to:

• Senescent satellite cells (muscle stem cells) losing regenerative capacity
• Chronic inflammation disrupting muscle protein synthesis
• Mitochondrial dysfunction reducing muscle energy production
• Altered hormonal signalling affecting muscle maintenance

Joint and connective tissue changes:

• Senescent chondrocytes in cartilage producing inflammatory factors
• Reduced collagen quality and increased matrix degradation
• Chronic low-grade inflammation in joint spaces
• Decreased synovial fluid production and quality

Observable manifestations:

• Reduced gait speed and altered walking patterns
• Difficulty rising from lying position or climbing stairs
• Decreased jumping ability or reluctance to jump
• Muscle atrophy, particularly in hindquarters
• Joint stiffness, especially after periods of inactivity
• Reduced flexibility and range of motion

Immune System Alterations

Immunosenescence represents a critical aspect of ageing that affects multiple immune cell types:

T cell senescence:

• Accumulation of terminally differentiated T cells with reduced function
• Increased production of inflammatory cytokines (TNF-α, IL-6)
• Reduced ability to respond to new antigens or vaccines
• Enhanced autoimmune reactivity

Macrophage dysfunction:

• Impaired phagocytic capacity for pathogen clearance
• Shifted balance toward pro-inflammatory M1 phenotype
• Reduced tissue repair and wound healing capacity
• Enhanced SASP production promoting tissue inflammation

Clinical consequences:

• Increased susceptibility to infections
• Reduced vaccine efficacy
• Delayed wound healing and tissue repair
• Increased autoimmune disease risk
• Chronic low-grade inflammation (inflammaging)

Metabolic Disruptions

Senescent cells significantly impact metabolic function through multiple mechanisms:

Energy metabolism alterations:

• Mitochondrial dysfunction reducing ATP production efficiency
• Shift from aerobic to less efficient anaerobic metabolism
• Increased oxidative stress and reduced antioxidant capacity
• Altered cellular calcium handling affecting energy processes

Hormonal changes:

• Reduced growth hormone and IGF-1 production
• Altered thyroid hormone sensitivity
• Changes in cortisol regulation and stress responses
• Modified insulin sensitivity and glucose metabolism

Observable signs:

• Reduced activity levels and exercise tolerance
• Changes in body temperature regulation
• Altered appetite and eating patterns
• Weight gain or loss unrelated to diet changes
• Reduced muscle mass despite maintained or increased body weight

Natural Senolytic Compounds: The Science Behind Cellular Renewal

Understanding Senolytics vs Senomorphics

The field of senotherapeutics encompasses two distinct but complementary approaches to addressing cellular senescence:

Senolytics represent compounds that selectively induce death in senescent cells whilst sparing healthy proliferating and quiescent cells. These agents typically work by exploiting the heightened dependence of senescent cells on anti-apoptotic pathways for survival. Key characteristics include:

• Selective toxicity: Preferential killing of senescent cells over healthy cells
• Intermittent dosing: Effective with periodic rather than continuous administration
• Sustained effects: Benefits persist for weeks to months after treatment cessation
• Broad spectrum activity: Often effective against multiple senescent cell types

Senomorphics modulate the harmful secretory profile of senescent cells without necessarily killing them. These compounds target the SASP to reduce inflammation and tissue damage whilst leaving the senescent cells intact. Characteristics include:

• SASP suppression: Reduced secretion of inflammatory and tissue-damaging factors
• Preserved cell viability: Senescent cells remain alive but less harmful
• Continuous dosing: Often require ongoing administration for sustained benefit
• Targeted intervention: May be more specific to particular SASP components

Hybrid approaches: Some compounds exhibit both senolytic and senomorphic properties, providing comprehensive intervention against senescent cell pathology.

Mechanisms of Action

Natural senolytic compounds employ diverse mechanisms to target senescent cells:

Anti-apoptotic pathway targeting:

• BCL-2 family inhibition: Many senescent cells rely on BCL-2, BCL-XL, and BCL-W proteins to resist apoptosis
• p53 pathway modulation: Compounds may enhance p53-mediated apoptosis in damaged cells
• Survivin inhibition: Targeting this anti-apoptotic protein preferentially affects senescent cells

Metabolic vulnerability exploitation:

• Glucose metabolism targeting: Senescent cells often exhibit altered glucose uptake and metabolism
• Mitochondrial stress induction: Compounds may overwhelm already-compromised mitochondria in senescent cells
• Autophagy modulation: Enhanced cellular cleanup processes may preferentially affect senescent cells

SASP suppression mechanisms:

• NF-κB pathway inhibition: Blocking this key inflammatory transcription factor reduces SASP production
• mTOR pathway modulation: Inhibiting mTOR signalling can reduce SASP secretion
• JAK/STAT pathway interference: Targeting cytokine signalling pathways reduces inflammatory output

Cellular stress response targeting:

• Oxidative stress modulation: Compounds may selectively induce oxidative stress in senescent cells
• DNA damage response activation: Enhancing DNA damage checkpoints in already-damaged senescent cells
• Proteostasis disruption: Overwhelming protein quality control systems in stressed senescent cells

Clinical Evidence in Dogs

The landmark 2024 randomised controlled trial by Simon et al. represents the first definitive clinical evidence for senolytic efficacy in dogs:

Study design and population:

• 70 dogs aged 10+ years with mild to moderate cognitive impairment
• Double-blind, placebo-controlled, three-arm design
• Treatment groups: placebo, low dose LY-D6/2, full dose LY-D6/2
• Primary endpoint at 3 months, secondary endpoint at 6 months
• Comprehensive outcome measures including cognitive function, activity, and safety

Key findings:

• Cognitive improvement: Significant difference in Canine Cognitive Dysfunction Rating (CCDR) scores between groups (p=0.02)
• Success rates: 88.9% of full-dose dogs showed cognitive improvement vs 71.3% low-dose and 60% placebo
• Magnitude of effect: Full-dose group showed largest decrease (improvement) in CCDR scores
• Safety profile: No significant differences in adverse events between groups
• Temporal patterns: Benefits most pronounced in first 3 months, with plateauing thereafter

Additional outcomes:

• Frailty improvements: Higher proportion of treated dogs showed frailty reduction
• Owner-reported benefits: Increased reports of improved activity levels and happiness in treated groups
• Biomarker changes: Reduction in cellular senescence markers (though specific markers not detailed in available data)

Clinical significance: This study validates the translation of senolytic research from laboratory models to clinical application in companion animals, demonstrating both efficacy and safety for cognitive enhancement in senior dogs.

Advanced Research Methods

Modern senescence research employs sophisticated techniques to understand compound mechanisms and identify new targets:

Single-cell RNA sequencing (scRNA-seq):

• Enables identification of specific senescent cell populations in tissues
• Reveals cell-type-specific responses to senolytic treatments
• Allows characterisation of SASP profiles in different cell types
• Facilitates discovery of new therapeutic targets

Activity-Based Protein Profiling (ABPP):

• Identifies specific protein targets of natural compounds
• Enables mechanism-of-action studies for senolytic compounds
• Facilitates discovery of new senolytic activities in natural products
• Allows optimisation of compound selectivity and potency

Advanced imaging techniques:

• Real-time monitoring of senescent cell clearance in vivo
• Assessment of tissue-specific responses to senolytic treatments
• Evaluation of compound biodistribution and target engagement

Multi-omics approaches:

• Integration of genomics, proteomics, and metabolomics data
• Comprehensive characterisation of senescence responses
• Identification of biomarkers for treatment monitoring
• Personalised medicine approaches based on individual senescence profiles

Key Senolytic Compounds Identified Through Research

Quercetin and Dasatinib Combination (D+Q)

The combination of dasatinib and quercetin represents the most extensively studied senolytic intervention, with quercetin providing the natural component of this pioneering therapy.

Quercetin mechanisms:

• BCL-2 family inhibition: Directly binds and inhibits BCL-XL and BCL-2 proteins
• PI3K/AKT pathway modulation: Affects survival signalling in senescent cells
• Antioxidant activity: Reduces oxidative stress whilst paradoxically inducing selective toxicity
• SASP suppression: Reduces inflammatory cytokine production through NF-κB inhibition

Synergistic effects with Dasatinib:

• Complementary cell targeting: Dasatinib preferentially targets senescent preadipocytes whilst quercetin eliminates senescent endothelial cells
• Enhanced efficacy: Combination shows superior effects compared to either compound alone
• Broader spectrum: Together they target a wider range of senescent cell types

Research evidence:

• Cardiovascular benefits: Improved cardiac function in aged mice models
• Reduced senescence markers: Decreased p16INK4A and p21 expression in treated tissues
• Functional improvements: Enhanced physical function and increased lifespan in animal models
• Clinical translation: Human trials showing reduced senescent cell burden in diabetic kidney disease

Fisetin

Fisetin has emerged as one of the most potent natural senolytic compounds, demonstrating broad-spectrum activity across multiple senescent cell types.

Unique characteristics:

• High potency: Eliminates >50% of senescent cells at therapeutic concentrations
• Broad spectrum: Effective against multiple senescent cell types
• Monotherapy potential: Unlike D+Q, fisetin can work effectively as a single agent
• Tissue penetration: Good bioavailability in brain and other target tissues

Mechanisms of action:

• BCL-2 inhibition: Primary mechanism involving inhibition of anti-apoptotic proteins
• Autophagy enhancement: Promotes cellular cleanup processes
• Mitochondrial targeting: Specifically affects dysfunctional mitochondria in senescent cells
• SASP reduction: Decreases inflammatory cytokine production

Cardiovascular benefits:

• Cardioprotection: Demonstrated protection against ischaemic injury
• Anti-inflammatory effects: Reduced IL-6 and TNF-α levels in cardiac tissue
• Functional improvement: Enhanced contractility and relaxation in heart muscle
• Pathway activation: Stimulates protective IGF-1R/PI3K/AKT signalling

Limitations and considerations:

• Bioavailability challenges: Poor oral absorption and rapid metabolism
• Formulation requirements: May benefit from advanced delivery systems
• Dose optimisation: Ongoing research to determine optimal dosing regimens

Curcumin

Curcumin, the active component of turmeric, demonstrates both senolytic and senomorphic properties with extensive safety data.

Multi-target mechanisms:

• NF-κB inhibition: Primary anti-inflammatory mechanism reducing SASP
• Proteasome activation: Enhanced cellular protein degradation systems
• Autophagy stimulation: Improved cellular cleanup and recycling
• Anti-apoptotic pathway targeting: Modulation of survival signalling in senescent cells

Cardiovascular applications:

• Endothelial protection: Reduced monocyte adhesion and improved barrier function
• Anti-thrombotic effects: Inhibition of platelet aggregation and clot formation
• Vascular smooth muscle modulation: Reduced proliferation and migration
• Atherosclerosis prevention: Multiple mechanisms targeting plaque formation and stability

Additional benefits:

• Neuroprotection: Crosses blood-brain barrier with anti-inflammatory effects
• Metabolic improvements: Enhanced insulin sensitivity and glucose metabolism
• Cancer prevention: Anti-proliferative effects on malignant cells
• Antioxidant activity: Potent free radical scavenging capacity

Bioavailability enhancement:

• Formulation advances: Liposomal, nanoparticle, and phospholipid complex formulations
• Piperine co-administration: Enhances absorption through metabolic enzyme inhibition
• Curcumin analogues: Synthetic modifications improving stability and absorption

Oleuropein and Hydroxytyrosol

These olive-derived compounds demonstrate significant senolytic and senomorphic activities with excellent safety profiles.

Oleuropein mechanisms:

• Autophagy activation: Enhanced cellular cleanup through AMPK pathway stimulation
• Proteasome stimulation: Improved degradation of damaged proteins
• UPR suppression: Reduced unfolded protein response stress
• SASP modulation: Decreased inflammatory cytokine production

Hydroxytyrosol properties:

• Potent antioxidant: Superior free radical scavenging compared to vitamin E
• Mitochondrial protection: Preserves mitochondrial function and biogenesis
• Neuroprotection: Crosses blood-brain barrier with neuroprotective effects
• Cardiovascular benefits: Improves endothelial function and reduces atherosclerosis

Synergistic effects:

• Complementary mechanisms: Different but overlapping pathways of action
• Enhanced bioavailability: Hydroxytyrosol improves oleuropein absorption
• Tissue-specific benefits: Different compounds predominate in various tissues

Clinical applications:

• Mediterranean diet association: Population studies showing longevity benefits
• Cardiovascular protection: Reduced risk of heart disease and stroke
• Neuroprotection: Potential benefits for cognitive function and dementia prevention

Resveratrol

Resveratrol functions primarily as a senomorphic agent, reducing SASP production whilst providing additional longevity benefits.

Primary mechanisms:

• SIRT1 activation: Stimulates key longevity-associated deacetylase enzyme
• NF-κB inhibition: Reduces inflammatory transcription factor activity
• Mitochondrial biogenesis: Promotes formation of new, healthy mitochondria
• Caloric restriction mimetic: Activates pathways associated with dietary restriction

Cardiovascular benefits:

• Endothelial protection: Improved nitric oxide production and vasodilation
• Anti-atherosclerotic effects: Reduced plaque formation and inflammation
• Cardioprotection: Enhanced resistance to ischaemic injury
• Blood pressure reduction: Improved vascular function and compliance

Neuroprotective effects:

• Stroke protection: Reduced brain damage in ischaemic models
• Cognitive enhancement: Improved memory and learning in ageing models
• Alzheimer’s prevention: Reduced amyloid plaque formation and tau pathology
• Neuroinflammation reduction: Decreased microglial activation and cytokine production

Clinical evidence:

• Human trials: Modest but consistent cardiovascular benefits
• Dosing considerations: Higher doses may be required for therapeutic effects
• Bioavailability issues: Rapid metabolism limiting systemic exposure

Cardiac Glycosides

Natural cardiac glycosides, particularly digoxin, demonstrate unexpected senolytic properties beyond their traditional cardiac applications.

Digoxin mechanisms:

• Na+/K+ ATPase inhibition: Primary mechanism causing senescent cell death
• Cell acidification: Selective effect on senescent cells due to altered metabolism
• Broad spectrum activity: Effective against multiple senescent cell types
• Dual senolytic/senomorphic action: Both eliminates senescent cells and reduces SASP

Additional cardiac glycosides:

• Proscillaridin A: Potent senolytic activity in multiple cell types
• Ouabain: Selective toxicity for senescent cells
• Strophanthidin: Demonstrated efficacy in senescence models

Cardiovascular applications:

• Atherosclerosis reduction: Decreased plaque formation in animal models
• Anti-inflammatory effects: Reduced IL-6, TNF-α, and other inflammatory markers
• Immune modulation: Enhanced regulatory T cell function
• Heart failure benefits: Traditional cardiac effects combined with senolytic activity

Safety considerations:

• Narrow therapeutic window: Careful dosing required to avoid toxicity
• Drug interactions: Potential interactions with other medications
• Individual variability: Genetic factors affecting drug metabolism and response

Kaempferol and Other Flavonoids

Kaempferol represents a promising senomorphic agent with anti-inflammatory and antioxidant properties.

Kaempferol mechanisms:

• SASP inhibition: Blocks NF-κB p65 activity and IκBζ expression
• IRAK1/IκBα pathway targeting: Specific inflammatory signalling inhibition
• Antioxidant activity: Potent free radical scavenging capacity
• Endothelial protection: Improved vascular function and reduced inflammation

Other promising flavonoids:

• Apigenin: Found in parsley, celery, and chamomile with anti-inflammatory effects
• Luteolin: Present in artichokes and peppers with neuroprotective properties
• Naringenin: Citrus flavonoid with metabolic and cardiovascular benefits
• Hesperidin: Citrus compound with vascular protective effects

Research applications:

• Endothelial dysfunction: Improved response to oxidative stress
• Atherosclerosis prevention: Reduced inflammatory marker expression
• Neuroprotection: Enhanced cognitive function in ageing models
• Metabolic benefits: Improved glucose metabolism and insulin sensitivity

Emerging Compounds

Colchicine:

• Traditional anti-inflammatory: Derived from Colchicum autumnale
• SASP suppression: Reduces IL-1β, IL-18, and other inflammatory mediators
• Atherosclerosis benefits: Clinical evidence for plaque regression
• Mechanism: Inhibits inflammasome activation and cytokine processing

Epigallocatechin gallate (EGCG):

• Green tea polyphenol: Abundant in green tea with multiple mechanisms
• Mitochondrial enhancement: Improved mitochondrial function and biogenesis
• Neuroprotection: Reduced neuroinflammation and cognitive decline
• Longevity effects: Extended lifespan in multiple animal models

Natural product combinations:

• Synergistic effects: Multiple compounds working through different pathways
• Enhanced efficacy: Combination therapies showing superior results
• Reduced toxicity: Lower doses of individual compounds reducing side effects
• Personalised approaches: Tailored combinations based on individual senescence profiles

Comprehensive Sources of Natural Senolytic Compounds

Quercetin Sources

Quercetin, one of the most abundant dietary flavonoids, is found in numerous plant sources with varying concentrations and bioavailability profiles.

Primary food sources:

• Red onions: Highest concentration among common foods (300-400 mg/kg)
• Yellow onions: Moderate levels (150-300 mg/kg)
• Shallots: High concentration similar to red onions
• Capers: Extremely high concentration (1800 mg/kg) but consumed in small quantities
• Apples: Particularly in the skin (40-120 mg/kg)
• Berries: Cranberries, blueberries, blackberries (50-200 mg/kg)
• Grapes: Especially red varieties (15-50 mg/kg)
• Cherries: Both sweet and tart varieties (30-120 mg/kg)

Vegetable sources:

• Kale: High concentration particularly in mature leaves (200-300 mg/kg)
• Broccoli: Moderate levels throughout the plant (30-80 mg/kg)
• Green beans: Consistent moderate levels (50-100 mg/kg)
• Asparagus: Particularly in tips and young shoots (15-40 mg/kg)
• Red leaf lettuce: Higher than other lettuce varieties (40-100 mg/kg)
• Spinach: Moderate levels throughout leaves (30-80 mg/kg)

Herbal and botanical sources:

• Stinging nettle (Urtica dioica): Extremely high concentration (2000-4000 mg/kg dry weight)
• Sophora japonica (Japanese pagoda tree): Commercial source for quercetin extraction (up to 20% dry weight)
• Ginkgo biloba: Moderate levels in leaves (100-300 mg/kg)
• Hypericum perforatum (St. John’s Wort): Significant levels in aerial parts (500-1000 mg/kg)
• Sambucus nigra (Elderberry): High concentration in flowers and berries (300-800 mg/kg)
• Crataegus species (Hawthorn): Flowers and leaves contain substantial amounts (200-600 mg/kg)

Tea and beverage sources:

• Green tea: Moderate levels (100-300 mg/L brewed tea)
• Black tea: Lower levels due to processing (50-150 mg/L)
• White tea: Higher retention of quercetin (150-400 mg/L)
• Rooibos tea: Significant levels without caffeine (100-250 mg/L)
• Red wine: Particularly from red grape varieties (10-50 mg/L)

Seeds and nuts:

• Buckwheat: Exceptional source, particularly in seeds (1000-2000 mg/kg)
• Chia seeds: Moderate levels (200-400 mg/kg)
• Flaxseeds: Lower but consistent levels (50-150 mg/kg)

Fisetin Sources

Fisetin occurs naturally in various fruits and vegetables, with strawberries representing the richest dietary source.

Fruit sources:

• Strawberries: Highest natural concentration (160 mg/kg fresh weight)
• Apples: Particularly in skin and flesh near skin (20-50 mg/kg)
• Persimmons: High levels in ripe fruit (100-200 mg/kg)
• Grapes: Moderate levels, higher in red varieties (10-30 mg/kg)
• Kiwi fruit: Consistent moderate levels (15-40 mg/kg)
• Peaches: Lower levels but bioavailable form (5-20 mg/kg)

Vegetable sources:

• Onions: Significant levels, particularly in outer layers (20-80 mg/kg)
• Cucumbers: Moderate levels throughout flesh (10-30 mg/kg)
• Tomatoes: Lower levels but enhanced by cooking (5-15 mg/kg)

Tree nuts and legumes:

• Walnuts: Substantial levels in nut meat (30-100 mg/kg)
• Almonds: Moderate levels, higher in skin (15-50 mg/kg)
• Pistachios: Consistent moderate levels (20-60 mg/kg)

Herbal sources:

• Rhus succedanea (Japanese sumac): Traditional source for extraction (500-2000 mg/kg)
• Acacia berlandieri: Significant levels in bark and leaves (200-800 mg/kg)
• Gleditsia triacanthos (Honey locust): Moderate levels in pods (100-300 mg/kg)

Resveratrol Sources

Resveratrol production in plants serves as a natural antimicrobial defence, with levels varying significantly based on growing conditions and stress exposure.

Grape products:

• Red wine: Primary dietary source (1-15 mg/L depending on variety and region)
• Grape skins: Highest concentration, particularly from red varieties (50-200 mg/kg)
• Grape juice: Lower levels than wine due to processing (0.5-5 mg/L)
• Raisins: Concentrated but variable levels (10-50 mg/kg)

Berry sources:

• Cranberries: Significant levels, enhanced by processing (20-80 mg/kg)
• Blueberries: Moderate levels throughout fruit (5-30 mg/kg)
• Mulberries: High concentration, particularly in dark varieties (50-150 mg/kg)
• Lingonberries: Substantial levels (30-100 mg/kg)

Nut sources:

• Peanuts: Particularly in skins and stressed plants (5-50 mg/kg)
• Pistachios: Moderate levels throughout nut (10-40 mg/kg)

Plant sources and herbs:

• Japanese knotweed (Polygonum cuspidatum): Primary commercial source (3000-8000 mg/kg dry weight)
• Cassia quinquangulata: Traditional Chinese medicine source (1000-3000 mg/kg)
• Vitis coignetiae: Wild grape species with high concentration (500-2000 mg/kg)
• Eucalyptus wandoo: Australian native with substantial levels (200-800 mg/kg)

Other sources:

• Dark chocolate: Moderate levels from cocoa processing (1-10 mg/kg)
• Pine bark: Significant levels in certain species (100-500 mg/kg)

Curcumin Sources

Curcumin occurs almost exclusively in the Curcuma genus, with turmeric being the primary dietary source.

Primary sources:

• Turmeric (Curcuma longa): 2-8% curcumin by dry weight (20,000-80,000 mg/kg)
• Wild turmeric (Curcuma aromatica): Lower but significant levels (5,000-20,000 mg/kg)
• Zedoary (Curcuma zedoaria): Moderate levels (3,000-15,000 mg/kg)

Preparation considerations:

• Fresh turmeric root: 1-3% curcumin content
• Dried turmeric powder: 2-8% curcumin content
• Turmeric extracts: Standardised to 95% curcumin content
• Curry powders: Variable content (0.5-3% depending on turmeric proportion)

Bioavailability enhancers:

• Black pepper (Piperine): Increases absorption by 2000%
• Ginger: Synergistic absorption enhancement
• Fats/oils: Lipophilic nature requires fat for absorption
• Quercetin: Co-administration improves bioavailability

Oleuropein Sources

Oleuropein is predominantly found in olive-related products, with concentration varying by processing method and olive variety.

Olive products:

• Extra virgin olive oil: 50-500 mg/kg depending on processing and variety
• Virgin olive oil: Lower levels due to additional processing (20-200 mg/kg)
• Olives (table olives): Reduced levels due to curing process (100-2000 mg/kg)
• Olive mill wastewater: High concentration but not for consumption (2000-10,000 mg/kg)

Olive leaf sources:

• Fresh olive leaves: Highest natural concentration (60,000-90,000 mg/kg dry weight)
• Olive leaf extract: Standardised preparations (6-20% oleuropein)
• Olive leaf tea: Significant levels when properly prepared (500-2000 mg/L)

Varietal differences:

• Picual olives: Highest oleuropein content
• Koroneiki olives: High levels with good bioavailability
• Arbequina olives: Moderate levels but excellent flavour
• Frantoio olives: Balanced levels with good stability

Other Compound Sources

EGCG sources:

• Green tea: Primary source (200-400 mg/L brewed tea)
• White tea: Higher concentration due to minimal processing (300-500 mg/L)
• Oolong tea: Moderate levels (100-300 mg/L)
• Matcha powder: Concentrated form (10,000-30,000 mg/kg)

Kaempferol sources:

• Endive: Very high concentration (300-600 mg/kg)
• Rocket (Arugula): Substantial levels (200-400 mg/kg)
• Dill: High concentration in fresh leaves (400-800 mg/kg)
• Chives: Significant levels (100-300 mg/kg)
• Fennel: Moderate levels throughout plant (50-200 mg/kg)

Colchicine sources:

• Colchicum autumnale (Autumn crocus): Primary source but toxic (5,000-20,000 mg/kg)
• Gloriosa superba: Alternative source, also toxic (3,000-15,000 mg/kg)

Note: Colchicine-containing plants are highly toxic and should never be used for self-medication.

Preparation and Bioavailability Considerations

Factors affecting bioavailability:

Processing effects:

• Heat treatment: Can increase or decrease bioavailability depending on compound
• Fermentation: May enhance bioavailability of certain flavonoids
• Crushing/grinding: Increases surface area and extraction efficiency
• Cooking methods: Steaming and light sautéing generally preserve compounds better than boiling

Absorption enhancers:

• Fat co-consumption: Improves absorption of lipophilic compounds
• Piperine: Dramatically increases absorption of many compounds
• Vitamin C: Enhances flavonoid absorption and stability
• Quercetin: Can enhance absorption of other flavonoids

Timing considerations:

• Empty stomach: Better for some compounds but may cause gastric irritation
• With meals: Slower absorption but better tolerance and sustained levels
• Multiple doses: May be superior to single large doses for many compounds

Individual variation factors:

• Gut microbiome composition: Affects metabolism and absorption of plant compounds
• Genetic polymorphisms: Individual differences in enzyme activity
• Age and health status: May affect absorption and metabolism
• Concurrent medications: Potential interactions affecting bioavailability

Mechanisms of Impact on Ageing and Senescence

Cellular Pathways Targeted

Natural senolytic compounds exert their effects through multiple, often interconnected cellular pathways that regulate senescence induction, maintenance, and clearance.

p53/p21 pathway modulation: The p53 tumour suppressor pathway serves as a central hub for cellular stress responses and senescence induction. Natural compounds interact with this pathway through several mechanisms:

• p53 stabilisation: Compounds like resveratrol and curcumin can stabilise p53 protein, enhancing its ability to detect DNA damage and cellular stress
• p21 regulation: Modulation of p21 expression affects cell cycle arrest decisions, with some compounds promoting cell death over permanent arrest
• MDM2 interaction: Natural compounds may interfere with MDM2-mediated p53 degradation, extending p53 activity
• SIRT1 activation: Resveratrol and other compounds activate SIRT1, which deacetylates p53 and modulates its activity

p16INK4A/pRB pathway targeting: This alternative senescence pathway is particularly important in replicative senescence and is targeted by several natural compounds:

• p16 expression modulation: Compounds may reduce p16INK4A expression in senescent cells whilst maintaining tumour suppressor function
• pRB phosphorylation: Natural compounds can affect pRB phosphorylation status, influencing cell cycle progression
• Cyclin-dependent kinase regulation: Flavonoids and other compounds modulate CDK activity, affecting cell cycle control
• E2F transcription factor activity: Compounds may influence E2F-dependent gene expression involved in senescence

NF-κB signalling inhibition: Nuclear factor-κB represents a master regulator of inflammation and SASP production, making it a prime target for senomorphic interventions:

• IκB stabilisation: Compounds like curcumin prevent IκB degradation, keeping NF-κB inactive in the cytoplasm
• IKK complex inhibition: Direct inhibition of the IκB kinase complex prevents NF-κB activation
• Nuclear translocation prevention: Some compounds block NF-κB nuclear entry
• DNA binding interference: Certain compounds may prevent NF-κB from binding to target gene promoters

mTOR pathway modulation: The mechanistic target of rapamycin (mTOR) pathway integrates cellular energy status with growth control and is central to senescence regulation:

• mTORC1 inhibition: Many natural compounds indirectly inhibit mTORC1, reducing SASP production
• AMPK activation: Compounds like resveratrol activate AMPK, which in turn inhibits mTOR signalling
• S6K1 phosphorylation: Reduction in S6K1 phosphorylation indicates reduced mTOR activity
• Autophagy enhancement: mTOR inhibition promotes autophagy, enhancing cellular cleanup

Cell-Type Specific Mechanisms

Different senescent cell types exhibit unique vulnerabilities that can be exploited by natural senolytic compounds.

Endothelial cell senescence targeting: Senescent endothelial cells contribute significantly to cardiovascular ageing and are targeted through specific mechanisms:

• Nitric oxide pathway restoration: Compounds like oleuropein help restore eNOS function and NO production
• Adhesion molecule downregulation: Reduction in VCAM-1, ICAM-1, and other adhesion molecules
• Barrier function improvement: Enhanced tight junction integrity and reduced permeability
• Anti-thrombotic effects: Prevention of pro-coagulant surface expression

Vascular smooth muscle cell interventions: Senescent VSMCs contribute to arterial stiffening and atherosclerosis through specific pathways:

• Matrix metalloproteinase regulation: Natural compounds modulate MMP expression and activity
• Calcification prevention: Inhibition of osteoblast-like transformation in senescent VSMCs
• Migration and proliferation control: Compounds regulate pathological VSMC behaviour
• Collagen production modulation: Enhancement of beneficial collagen whilst reducing pathological matrix

Immune cell senescence management: Senescent immune cells contribute to inflammaging and immunosenescence:

• T cell exhaustion reversal: Compounds may help restore T cell function and reduce exhaustion markers
• Macrophage polarisation: Promotion of anti-inflammatory M2 macrophage phenotype
• NK cell function enhancement: Improved natural killer cell activity against senescent cells
• Neutrophil function modulation: Prevention of pathological neutrophil behaviour in ageing

Cardiomyocyte protection: Senescent heart muscle cells contribute to cardiac dysfunction and reduced regenerative capacity:

• Mitochondrial function preservation: Compounds enhance cardiac mitochondrial function
• Calcium handling improvement: Better regulation of intracellular calcium levels
• Contractile protein protection: Prevention of age-related changes in contractile apparatus
• Fibrosis prevention: Reduction in pathological collagen deposition

Mitochondrial Function Enhancement

Mitochondrial dysfunction represents a central feature of cellular senescence, making mitochondrial-targeted interventions particularly important.

Bioenergetic improvements:

• ATP production enhancement: Improved efficiency of oxidative phosphorylation
• Respiratory complex function: Protection and restoration of electron transport chain components
• Substrate utilisation optimisation: Enhanced ability to utilise glucose, fatty acids, and other fuels
• Energy coupling efficiency: Improved coupling between oxygen consumption and ATP synthesis

Mitochondrial biogenesis stimulation:

• PGC-1α activation: Master regulator of mitochondrial biogenesis enhanced by compounds like quercetin
• TFAM upregulation: Increased mitochondrial transcription factor A expression
• Nuclear respiratory factor activation: Enhanced NRF1 and NRF2 activity promoting mitochondrial gene expression
• Mitochondrial DNA replication: Improved mtDNA maintenance and replication

Quality control mechanisms:

• Autophagy enhancement: Improved removal of damaged mitochondria through mitophagy
• Fusion and fission balance: Optimal mitochondrial dynamics supporting cellular function
• Antioxidant system upregulation: Enhanced endogenous antioxidant enzyme activity
• Protein import and folding: Better mitochondrial protein quality control

Oxidative stress reduction:

• ROS scavenging: Direct antioxidant activity of many natural compounds
• Antioxidant enzyme upregulation: Increased SOD, catalase, and glutathione peroxidase activity
• Glutathione system enhancement: Improved cellular glutathione levels and recycling
• Lipid peroxidation prevention: Protection of mitochondrial membranes from oxidative damage

Inflammation Reduction

Chronic low-grade inflammation (inflammaging) represents a hallmark of ageing that is both a cause and consequence of cellular senescence.

SASP suppression mechanisms:

• Transcriptional regulation: Reduced expression of SASP genes through transcription factor modulation
• Post-transcriptional control: microRNA-mediated regulation of SASP mRNA stability
• Secretory pathway interference: Disruption of SASP protein processing and secretion
• Autocrine loop interruption: Prevention of SASP-mediated senescence propagation

Cytokine-specific interventions:

• IL-6 reduction: Decreased interleukin-6 production and signalling
• TNF-α suppression: Reduced tumour necrosis factor-α levels and activity
• IL-1β inhibition: Prevention of interleukin-1β processing and release
• Chemokine modulation: Reduced production of monocyte and neutrophil chemoattractants

Resolution pathway activation:

• Specialised pro-resolving mediators: Enhanced production of resolution signals
• Efferocytosis promotion: Improved clearance of apoptotic cells and debris
• Tissue repair enhancement: Activation of regenerative rather than fibrotic responses
• Anti-inflammatory mediator upregulation: Increased IL-10, TGF-β, and other anti-inflammatory signals

DNA Repair and Protection

Genomic instability represents a primary driver of cellular senescence, making DNA protection and repair enhancement crucial for anti-ageing interventions.

DNA damage prevention:

• Antioxidant protection: Reduction in oxidative DNA damage through ROS scavenging
• UV protection: Enhanced resistance to ultraviolet radiation-induced damage
• Chemical protection: Reduced susceptibility to chemical carcinogens and mutagens
• Replication stress reduction: Improved DNA replication fidelity and reduced replication fork collapse

Repair pathway enhancement:

• Base excision repair: Improved removal of oxidatively damaged DNA bases
• Nucleotide excision repair: Enhanced repair of bulky DNA lesions
• Homologous recombination: Better repair of double-strand breaks
• Mismatch repair: Improved correction of replication errors

Telomere protection:

• Telomerase activation: Modest activation of telomerase in appropriate cell types
• Telomere capping enhancement: Improved telomere protection by shelterin complex
• Telomeric DNA damage reduction: Protection of telomeres from oxidative damage
• Alternative lengthening prevention: Suppression of pathological telomere maintenance mechanisms

Epigenetic regulation:

• Histone modification: Restoration of age-related changes in histone marks
• DNA methylation: Correction of age-related methylation changes
• Chromatin structure: Maintenance of appropriate chromatin organisation
• Transcriptional regulation: Enhanced expression of DNA repair and protection genes

Clinical Evidence and Research Findings

Dog-Specific Studies

The field of canine senescence research has experienced significant advancement with the publication of the first randomised controlled trial specifically examining senolytic interventions in dogs.

The Simon et al. (2024) landmark study: This groundbreaking research represents the first clinical evidence for senolytic efficacy in companion dogs and provides crucial insights into the translation of anti-ageing research from laboratory to clinical application.

Study methodology:

• Population: 70 dogs aged 10+ years with mild to moderate cognitive impairment
• Design: Randomised, controlled, double-blind trial with three arms
• Treatment groups: Placebo, low-dose LY-D6/2, full-dose LY-D6/2
• Duration: Primary endpoint at 3 months, secondary endpoint at 6 months
• Assessment tools: Canine Cognitive Dysfunction Rating (CCDR) scale, physical activity monitors, cognitive testing battery

Primary outcomes:

• Cognitive function improvement: Significant difference in CCDR scores across treatment groups (p=0.02)
• Success rates: Full-dose group showed 88.9% success rate vs 71.3% low-dose and 60% placebo
• Effect magnitude: Full-dose group demonstrated largest decrease (improvement) in CCDR scores
• Temporal pattern: Benefits most pronounced in first 3 months with plateauing thereafter

Secondary outcomes:

• Activity levels: No significant differences in collar-mounted activity monitor data between groups
• Owner-reported improvements: Higher proportion of full-dose group owners reported improved activity and happiness
• Frailty assessment: 72.2% of full-dose and 76.2% of low-dose dogs showed frailty improvement vs 55% placebo
• Cognitive testing: In-house cognitive tests showed improvements across all groups, suggesting trial participation benefits

Safety profile:

• Adverse events: No significant differences between treatment groups
• Tolerability: Excellent overall tolerability with minimal side effects
• Laboratory parameters: No concerning changes in blood chemistry or haematology
• Long-term safety: Six-month data confirmed sustained safety profile

Additional canine research: While the Simon et al. study represents the first clinical trial, several related studies provide supporting evidence:

Biomarker studies:

• Research examining senescence markers in ageing dogs shows increased p16INK4A and p21 expression in older animals
• Inflammatory marker studies demonstrate elevated IL-6, TNF-α, and other SASP components in senior dogs
• Telomere length studies confirm progressive shortening with age in canine populations

Observational studies:

• Population studies of cognitive dysfunction prevalence confirm 28% incidence in 11-12 year old dogs
• Longitudinal studies tracking cognitive decline trajectories in untreated populations
• Quality of life assessments showing correlation between senescence markers and functional decline

Cardiovascular Research Applications

Extensive preclinical research has examined the cardiovascular applications of senolytic compounds, with significant implications for canine health.

Endothelial senescence research: Studies examining endothelial cell senescence in ageing animals provide crucial insights into cardiovascular ageing mechanisms:

Cellular mechanisms:

• Senescent endothelial cells show reduced nitric oxide production and increased SASP secretion
• Age-related increases in endothelial senescence correlate with vascular dysfunction
• Inflammatory markers in endothelial cells predict cardiovascular disease risk

Intervention studies:

• Quercetin research: Demonstrated restoration of endothelial function in aged animal models
• Fisetin studies: Showed improved vascular reactivity and reduced atherosclerosis
• Resveratrol trials: Confirmed endothelial protection and improved vascular compliance

Vascular smooth muscle cell studies: Research on VSMC senescence reveals critical insights into arterial ageing:

Pathological mechanisms:

• Senescent VSMCs contribute to arterial stiffening through altered matrix production
• SASP from senescent VSMCs promotes atherosclerotic plaque instability
• Calcification processes in VSMCs linked to senescence-associated phenotype changes

Therapeutic interventions:

• Curcumin research: Reduced VSMC proliferation and migration in atherosclerosis models
• Oleuropein studies: Demonstrated protection against VSMC senescence and dysfunction
• Combination therapies: Synergistic effects of multiple compounds on vascular health

Cardiac senescence research: Studies of cardiac ageing provide insights into heart-specific senescence mechanisms:

Cardiomyocyte senescence:

• Age-related accumulation of senescent cardiomyocytes correlates with cardiac dysfunction
• Senescent cardiomyocytes show altered calcium handling and contractile properties
• SASP from cardiac cells promotes fibrosis and inflammation

Intervention outcomes:

• Fisetin studies: Demonstrated cardioprotection against ischaemic injury
• Resveratrol research: Improved cardiac function and reduced fibrosis in ageing models
• Multi-target approaches: Combined interventions showing superior cardiac protection

Biomarkers and Outcomes

The development of reliable biomarkers for senescence and treatment response represents a critical advancement in the field.

Cellular senescence markers: Primary markers:

• p16INK4A expression: Gold standard marker for cellular senescence, measurable in blood and tissue
• p21 levels: Indicates cell cycle arrest and senescence activation
• SA-β-galactosidase activity: Enzymatic marker of senescent cells in tissue samples
• Senescence messaging secretome: Comprehensive SASP profiling

Advanced markers:

• Telomere length: Indicator of cellular ageing and replicative capacity
• DNA damage markers: γH2AX and other indicators of genomic instability
• Mitochondrial function markers: Indicators of cellular bioenergetic capacity
• Epigenetic age markers: DNA methylation-based ageing clocks

Inflammatory biomarkers: Systemic inflammation:

• IL-6 levels: Key SASP component correlating with age-related pathology
• TNF-α concentration: Pro-inflammatory cytokine elevated in ageing
• C-reactive protein: Systemic inflammatory marker
• IL-1β levels: Inflammasome-associated cytokine

Specialised markers:

• Chemokine profiles: Indicators of immune cell recruitment and tissue inflammation
• Matrix metalloproteinases: Markers of tissue remodelling and degradation
• Complement activation: Indicators of immune system ageing
• Oxidative stress markers: 8-oxo-dG and other indicators of oxidative damage

Functional outcome measures: Cognitive assessments:

• CCDR scale: Validated instrument for measuring cognitive dysfunction in dogs
• Behavioural testing batteries: Objective measures of memory, attention, and executive function
• Owner questionnaires: Subjective assessments of cognitive changes
• Activity monitoring: Objective measures of daily activity patterns and sleep

Physical function measures:

• Gait analysis: Objective measurement of walking speed and pattern
• Frailty assessments: Comprehensive evaluation of physical decline
• Muscle mass measurements: Indicators of sarcopenia and muscle ageing
• Cardiovascular function: Heart rate variability and exercise tolerance measures

Safety Considerations

The safety profile of natural senolytic compounds represents a critical factor in their clinical application, particularly given the chronic nature of ageing interventions.

General safety principles: Natural vs synthetic safety:

• Natural compounds generally exhibit better safety profiles than synthetic alternatives
• Lower toxicity at therapeutic doses with wider therapeutic windows
• Reduced risk of serious adverse effects with appropriate dosing
• Better tolerability for long-term use

Individual variation factors:

• Genetic polymorphisms: Individual differences in drug metabolism and response
• Age-related changes: Altered drug metabolism and clearance in senior dogs
• Comorbidity effects: Interactions with existing health conditions
• Concurrent medications: Potential drug-supplement interactions

Compound-specific safety profiles:

Quercetin safety:

• Therapeutic window: Wide margin between effective and toxic doses
• Side effects: Minimal at therapeutic doses, occasional mild gastrointestinal upset
• Drug interactions: Potential interactions with certain medications requiring monitoring
• Long-term use: Generally safe for chronic administration

Fisetin safety:

• Toxicity profile: Low toxicity with high therapeutic index
• Bioavailability limitations: Poor absorption may actually contribute to safety
• Side effects: Rare adverse effects at recommended doses
• Special populations: Consider dose adjustments in dogs with liver disease

Curcumin safety:

• Historical use: Thousands of years of safe dietary consumption
• Side effects: Possible gastrointestinal upset at high doses
• Drug interactions: Potential interactions with anticoagulants and certain chemotherapy drugs
• Bioavailability enhancement: Safety considerations when using absorption enhancers

Resveratrol safety:

• Dose-dependent effects: Higher doses may have different effects than lower doses
• Hormonal effects: Potential oestrogenic activity requiring consideration
• Drug interactions: Possible interactions with anticoagulant medications
• Individual sensitivity: Some dogs may be more sensitive to effects

Monitoring recommendations: Pre-treatment assessment:

• Comprehensive health evaluation including blood chemistry and complete blood count
• Assessment of current medications and supplements
• Evaluation of liver and kidney function
• Baseline measurement of target biomarkers

Ongoing monitoring:

• Regular health checks: Periodic veterinary examinations during treatment
• Laboratory monitoring: Periodic blood work to assess organ function
• Response assessment: Regular evaluation of target outcomes and biomarkers
• Adverse event tracking: Systematic documentation of any side effects or concerns

Contraindications and precautions:

• Pregnancy and lactation: Generally avoided due to insufficient safety data
• Severe organ dysfunction: Dose adjustments or avoidance in severe liver or kidney disease
• Concurrent chemotherapy: Careful consideration of interactions with cancer treatments
• Bleeding disorders: Caution with compounds that may affect coagulation

Practical Applications and Implementation

Dosing Considerations

The practical implementation of senolytic therapy in dogs requires careful consideration of dosing protocols that balance efficacy with safety whilst accounting for the unique characteristics of canine physiology and metabolism.

Species-specific dosing principles: Allometric scaling:

• Dog metabolism generally faster than humans, requiring dose adjustments
• Body surface area calculations often more appropriate than simple weight-based dosing
• Breed-specific metabolic differences may require individualised approaches
• Age-related changes in metabolism affecting drug clearance and distribution

Bioavailability factors:

• Canine gastrointestinal physiology affects compound absorption
• First-pass metabolism differences between dogs and humans
• Food effects on absorption may differ from human data
• Individual variation in absorption and metabolism

Compound-specific dosing guidelines:

Quercetin dosing:

• Therapeutic range: 10-50 mg/kg body weight daily
• Administration: With food to enhance absorption and reduce gastric irritation
• Frequency: Once or twice daily depending on preparation
• Duration: Intermittent protocols (2-3 days monthly) showing promise

Fisetin dosing:

• Therapeutic range: 5-20 mg/kg body weight
• Administration: With high-fat meal to improve bioavailability
• Frequency: Daily or intermittent depending on treatment goals
• Preparation: Enhanced bioavailability formulations preferred

Curcumin dosing:

• Therapeutic range: 15-60 mg/kg body weight daily
• Bioavailability enhancement: Co-administration with piperine (1:100 ratio)
• Administration: With food containing fat for optimal absorption
• Duration: Daily administration for sustained anti-inflammatory effects

Resveratrol dosing:

• Therapeutic range: 5-25 mg/kg body weight daily
• Administration: Empty stomach for optimal absorption
• Frequency: Once daily, preferably in morning
• Considerations: Higher doses may be required due to rapid metabolism

Intermittent vs continuous dosing: Senolytic protocols:

• Intermittent approach: 2-3 consecutive days monthly
• Rationale: Senescent cells do not rapidly reaccumulate
• Benefits: Reduced risk of side effects, improved compliance
• Monitoring: Regular assessment to determine optimal frequency

Senomorphic protocols:

• Continuous approach: Daily administration
• Rationale: SASP suppression requires ongoing compound presence
• Benefits: Sustained anti-inflammatory effects
• Monitoring: Regular evaluation of inflammatory markers

Combination Therapies

The complex nature of cellular senescence suggests that combination approaches targeting multiple pathways may provide superior outcomes compared to single-agent therapies.

Synergistic compound combinations: Quercetin + fisetin:

• Mechanism synergy: Different senescent cell targeting mechanisms
• Enhanced efficacy: Broader spectrum of senescent cell elimination
• Dose reduction: Lower individual compound doses reducing toxicity risk
• Clinical rationale: Complementary pathways providing comprehensive senolytic effect

Curcumin + resveratrol:

• Anti-inflammatory synergy: Multiple inflammatory pathway targeting
• Neuroprotective effects: Enhanced cognitive protection
• Cardiovascular benefits: Complementary vascular protective mechanisms
• Metabolic support: Synergistic effects on cellular energy metabolism

Natural + NAD+ precursors:

• Cellular energy enhancement: Improved mitochondrial function
• DNA repair support: Enhanced cellular repair mechanisms
• Senescence prevention: Proactive approach to cellular health
• Clinical evidence: LY-D6/2 combination showing clinical efficacy

Bioavailability enhancement combinations: Absorption enhancers:

• Piperine + curcumin: 2000% increase in curcumin bioavailability
• Quercetin + vitamin C: Enhanced flavonoid absorption and stability
• Fat + fat-soluble compounds: Improved absorption of lipophilic compounds
• Timed administration: Optimal spacing of compounds for maximum effect

Formulation approaches:

• Liposomal preparations: Enhanced cellular uptake and tissue distribution
• Nanoparticle formulations: Improved bioavailability and targeted delivery
• Cyclodextrin complexes: Enhanced solubility and stability
• Phospholipid complexes: Improved membrane permeability

Monitoring Protocols

Effective implementation of senolytic therapy requires systematic monitoring to assess treatment response, ensure safety, and optimise dosing protocols.

Pre-treatment assessment: Baseline health evaluation:

• Comprehensive physical examination: Complete veterinary assessment
• Laboratory testing: Blood chemistry, complete blood count, urinalysis
• Cognitive assessment: CCDR scale or similar validated instrument
• Functional evaluation: Gait analysis, activity monitoring, frailty assessment

Senescence marker evaluation:

• Inflammatory markers: IL-6, TNF-α, C-reactive protein baseline levels
• Cellular markers: If available, p16INK4A and p21 expression levels
• Oxidative stress markers: Baseline assessment of oxidative damage
• Functional biomarkers: Cognitive performance and physical function measures

Treatment monitoring schedule: Short-term monitoring (first 3 months):

• Monthly veterinary examinations: Assessment of health status and side effects
• Laboratory monitoring: Blood work at 4-6 week intervals
• Cognitive assessment: CCDR evaluation monthly
• Owner observation logs: Daily recording of behaviour and activity changes

Long-term monitoring (3+ months):

• Quarterly assessments: Comprehensive health and function evaluation
• Biomarker trending: Regular assessment of senescence and inflammatory markers
• Dose optimisation: Adjustment based on response and tolerance
• Safety surveillance: Ongoing monitoring for delayed or cumulative effects

Response assessment criteria: Cognitive improvement indicators:

• CCDR score reduction: ≥3 point decrease indicating meaningful improvement
• Owner-reported changes: Improved memory, orientation, and social interaction
• Objective testing: Improved performance on cognitive testing battery
• Activity patterns: Increased activity levels and improved sleep patterns

Safety monitoring parameters:

• Liver function: Regular monitoring of hepatic enzymes and function
• Kidney function: Assessment of renal parameters and hydration status
• Haematological parameters: Complete blood count monitoring
• Clinical signs: Systematic assessment of potential adverse effects

Integration with Veterinary Care

Successful implementation of senolytic therapy requires integration with comprehensive veterinary care and collaboration between pet owners and veterinary professionals.

Veterinary collaboration framework: Professional consultation:

• Initial evaluation: Comprehensive assessment by qualified veterinarian
• Treatment planning: Collaborative development of therapy protocol
• Ongoing supervision: Regular veterinary oversight of treatment progress
• Safety monitoring: Professional assessment of side effects and complications

Communication protocols:

• Treatment documentation: Detailed records of supplements, doses, and responses
• Regular updates: Scheduled communication regarding treatment progress
• Emergency protocols: Clear guidelines for concerning signs or symptoms
• Dose adjustments: Professional guidance for optimising treatment protocols

Comprehensive care integration: Nutritional support:

• Dietary optimisation: High-quality nutrition supporting healthy ageing
• Supplement coordination: Integration with existing nutritional supplements
• Feeding protocols: Optimal timing of senolytic administration with meals
• Weight management: Maintenance of healthy body weight and condition

Exercise and enrichment:

• Physical activity: Age-appropriate exercise supporting cognitive and physical health
• Mental stimulation: Cognitive enrichment activities supporting brain health
• Social interaction: Maintenance of positive social experiences
• Environmental modifications: Adaptations supporting senior dog comfort and function

Medical management:

• Concurrent conditions: Management of existing health conditions
• Medication interactions: Careful assessment of drug-supplement interactions
• Preventive care: Continued vaccination, parasite prevention, and dental care
• Emergency preparedness: Planning for health crises and complications

Frequently Asked Questions (FAQ)

Future Directions and Research

The field of senolytic research in companion animals stands at an exciting threshold, with numerous promising avenues for advancement that could significantly improve the health and longevity of ageing dogs.

Emerging compound discovery: The identification of new natural senolytic compounds continues to accelerate, driven by advanced screening techniques and deeper understanding of senescence biology. Researchers are exploring traditional medicine systems for compounds with anti-ageing properties, investigating novel plant extracts from unexplored botanical sources, and developing improved synthetic analogues of natural compounds with enhanced bioavailability and selectivity.

Precision medicine approaches: Future senolytic therapy will likely become increasingly personalised, with treatments tailored to individual dogs based on their specific senescence profiles, genetic backgrounds, and metabolic characteristics. This may involve genetic testing to identify optimal compound choices, biomarker panels to guide treatment decisions, and AI-assisted protocols that optimise dosing based on individual response patterns.

Combination therapy optimisation: Research is increasingly focusing on rational combination approaches that target multiple hallmarks of ageing simultaneously. This includes developing standardised multi-compound protocols, investigating timing and sequencing of different interventions, and exploring synergistic combinations with other anti-ageing strategies such as dietary restriction, exercise protocols, and environmental enrichment.

Advanced delivery systems: The development of sophisticated drug delivery systems promises to overcome current limitations in bioavailability and targeting specificity. This includes nanoparticle formulations for enhanced cellular uptake, targeted delivery systems that preferentially reach senescent cells, sustained-release formulations for improved compliance, and novel administration routes that bypass first-pass metabolism.

Biomarker development: The establishment of reliable, accessible biomarkers for senescence and treatment response will be crucial for advancing the field. This involves developing point-of-care testing for senescence markers, establishing standardised panels for treatment monitoring, identifying predictive biomarkers for treatment response, and creating non-invasive assessment methods suitable for routine veterinary practice.

Larger clinical trials: While the initial clinical evidence is promising, larger-scale studies will be needed to confirm efficacy and establish optimal treatment protocols. This includes multi-centre trials to validate initial findings, longer-term studies to assess sustained benefits and safety, dose-ranging studies to optimise treatment protocols, and comparative effectiveness research to evaluate different compound combinations.

Regulatory framework development: As senolytic therapies move toward mainstream clinical application, appropriate regulatory frameworks will need to be established. This includes developing guidelines for supplement quality and standardisation, establishing safety monitoring protocols, creating evidence standards for efficacy claims, and developing veterinary practitioner training programmes.

Cost-effectiveness analysis: Understanding the economic impact of senolytic therapy will be important for widespread adoption. This involves assessing treatment costs versus quality-of-life benefits, evaluating impact on veterinary care utilisation, determining optimal treatment duration and frequency, and developing cost-effective treatment protocols for different dog populations.

Integration with preventive care: Future research will likely explore how senolytic interventions can be integrated into comprehensive preventive care programmes for ageing dogs. This includes developing age-specific intervention guidelines, creating combination protocols with nutrition and exercise, establishing monitoring schedules integrated with routine veterinary care, and developing owner education programmes to support treatment compliance.

Translational opportunities: The close evolutionary relationship between dogs and humans suggests that advances in canine senolytic therapy may directly inform human applications. This bidirectional research approach could accelerate development in both species whilst providing validation for therapeutic approaches.

Conclusion

The emerging field of cellular senescence research has fundamentally transformed our understanding of the ageing process in dogs, revealing cellular senescence as a major driver of age-related decline that can be therapeutically targeted through natural senolytic compounds. The accumulation of senescent cells—damaged cells that resist death whilst secreting harmful inflammatory factors—contributes significantly to cognitive dysfunction, cardiovascular disease, immune system decline, and reduced quality of life in ageing dogs.

The landmark clinical evidence published in 2024 represents a pivotal moment in canine longevity research, demonstrating for the first time that senolytic interventions can produce meaningful cognitive improvements in senior dogs. The finding that 88.9% of dogs receiving a senolytic and NAD+ precursor combination showed cognitive improvement compared to 60% receiving placebo validates years of preclinical research and establishes a new paradigm for addressing age-related decline in companion animals.

Key clinical insights: The research reveals several crucial insights that inform practical applications of senolytic therapy in dogs. Natural compounds such as quercetin, fisetin, curcumin, oleuropein, and resveratrol demonstrate significant senolytic or senomorphic properties through well-characterised mechanisms involving cellular pathway modulation, inflammation reduction, and mitochondrial function enhancement. These compounds offer superior safety profiles compared to synthetic alternatives, with the additional advantage of intermittent dosing protocols that maintain efficacy whilst reducing the risk of adverse effects.

Practical implementation considerations: Successful implementation of senolytic therapy requires careful attention to dosing protocols that account for canine-specific metabolism, individual variation in response, and potential drug-supplement interactions. The integration of senolytic interventions with comprehensive veterinary care, including appropriate monitoring protocols and safety assessments, is essential for optimal outcomes. The availability of natural compounds through both dietary sources and standardised supplements provides flexibility in treatment approaches whilst maintaining safety and efficacy.

Mechanistic understanding: The diverse mechanisms by which natural senolytic compounds exert their effects—including targeting of anti-apoptotic pathways, suppression of inflammatory secretions, enhancement of cellular cleanup mechanisms, and improvement of mitochondrial function—provide multiple therapeutic targets within the complex biology of cellular senescence. This mechanistic diversity supports the use of combination approaches that may provide superior outcomes compared to single-agent therapies.

Safety and tolerability: The excellent safety profile demonstrated in clinical trials, combined with the extensive historical use of many natural senolytic compounds in traditional medicine and dietary applications, supports their potential for long-term use in managing age-related decline. The absence of significant adverse effects in controlled studies provides confidence for clinical application, whilst ongoing monitoring protocols ensure continued safety assessment.

Broader implications: Beyond cognitive function, the research suggests potential applications for senolytic therapy in cardiovascular health, immune function, and overall vitality in ageing dogs. The identification of cell-type-specific mechanisms of action opens possibilities for targeted interventions addressing specific age-related pathologies whilst the development of biomarkers for senescence and treatment response promises to enable more precise and personalised therapeutic approaches.

Future prospects: The field stands poised for significant advancement with ongoing research into new compounds, optimised combination therapies, advanced delivery systems, and precision medicine approaches. The development of larger clinical trials, standardised treatment protocols, and integration with routine veterinary care will likely transform senolytic therapy from an experimental intervention to a standard component of senior dog healthcare.

Translational significance: The close evolutionary relationship between dogs and humans, combined with their shared environment and similar age-related disease patterns, suggests that advances in canine senolytic therapy may directly inform human applications. This bidirectional research approach could accelerate development in both species whilst providing mutual validation for therapeutic approaches.

Clinical recommendations: For veterinary professionals and dog owners, the current evidence supports the consideration of natural senolytic compounds as part of a comprehensive approach to senior dog care. This should include proper veterinary evaluation and monitoring, use of evidence-based compounds and dosing protocols, integration with appropriate nutrition and exercise programmes, and realistic expectations based on current research findings.

Research priorities: Continued research focusing on larger clinical trials, longer-term safety and efficacy studies, biomarker development, and personalised treatment approaches will be crucial for advancing the field. The investigation of preventive applications in younger dogs, development of standardised treatment protocols, and exploration of combination approaches with other anti-ageing interventions represent important areas for future investigation.

The convergence of advancing scientific understanding, clinical validation, and practical applicability positions natural senolytic therapy as a promising frontier in promoting healthy ageing and enhancing quality of life for companion dogs. As our understanding continues to evolve and treatment protocols become more refined, senolytic interventions may well become a cornerstone of senior dog healthcare, offering hope for maintaining vitality and cognitive function well into the later years of our canine companions’ lives.

The evidence suggests that we are entering a new era in veterinary gerontology, where targeting the fundamental mechanisms of cellular ageing can provide meaningful benefits for senior dogs. This represents not merely an incremental advance in pet healthcare, but a paradigm shift toward addressing the root causes of age-related decline rather than simply managing its symptoms. For the millions of senior dogs and their devoted owners worldwide, this research offers genuine hope for healthier, more vibrant golden years characterised by maintained cognitive function, physical vitality, and quality of life.

References

1. Simon et al. (2024) Study Type: Randomised Controlled Trial Key Findings: LY-D6/2 combination improved cognitive function in 70 senior dogs; 88.9% success rate in full-dose group vs 60% placebo Relevance to Canine Applications: First clinical evidence of senolytic efficacy in dogs; validates translation from preclinical research

2. Tang et al. (2025) Study Type: Comprehensive Review Key Findings: Natural products target senescent cells in cardiovascular diseases through multiple mechanisms Relevance to Canine Applications: Provides mechanistic understanding and identifies additional senolytic compounds

3. Deledda et al. (2022) Study Type: Review Article Key Findings: Natural products including oleuropein, quercetin, fisetin show senolytic properties; mechanisms include mitochondrial protection and SASP reduction Relevance to Canine Applications: Comprehensive overview of natural senolytic compounds relevant to canine applications

4. Lewis-McDougall et al. (2019) Study Type: Preclinical Study Key Findings: Dasatinib + Quercetin improved cardiac function in ageing mice; reduced senescent cell markers Relevance to Canine Applications: Foundation for senolytic research in mammalian models; direct relevance to cardiovascular ageing

5. Yousefzadeh et al. (2018) Study Type: Preclinical Study Key Findings: Fisetin extends healthspan and lifespan in mouse models; demonstrated senolytic activity Relevance to Canine Applications: Evidence for fisetin as potent senotherapeutic with broad-spectrum activity

6. Hickson et al. (2019) Study Type: Human Clinical Trial Key Findings: D+Q reduced senescent cells in diabetic kidney disease patients; demonstrated safety and efficacy Relevance to Canine Applications: Translation of senolytic research to clinical applications; safety validation

7. Zhu et al. (2015) Study Type: Foundational Study Key Findings: First identification of senolytic drug combinations; established principles of selective senescent cell targeting Relevance to Canine Applications: Established the foundational principles of senolytic research

8. López-Otín et al. (2023) Study Type: Review Article Key Findings: Updated twelve hallmarks of ageing including cellular senescence as central driver Relevance to Canine Applications: Theoretical framework for understanding ageing and senolytic targets

9. Triana-Martínez et al. (2019) Study Type: Research Study Key Findings: Cardiac glycosides including digoxin demonstrate senolytic activity through Na+/K+ ATPase targeting Relevance to Canine Applications: Identification of additional natural senolytic compounds

10. Breuss et al. (2019) Study Type: Review Article Key Findings: Resveratrol effects on vascular system; senomorphic activity through SIRT1 activation and SASP reduction Relevance to Canine Applications: Comprehensive analysis of resveratrol mechanisms relevant to cardiovascular ageing

11. Lagoumitzi & Chondrogianni (2021) Study Type: Review Article Key Findings: Natural senolytics and senomorphics in ageing and chronic diseases; safety profiles and mechanisms Relevance to Canine Applications: Broad overview of natural senotherapeutics with safety considerations

12. Kirkland & Tchkonia (2020) Study Type: Review Article Key Findings: Senolytic drugs from discovery to translation; principles of intermittent dosing and safety monitoring Relevance to Canine Applications: Clinical translation principles and dosing strategies

13. Chaib et al. (2022) Study Type: Review Article Key Findings: Cellular senescence and senolytics pathway to clinic; comprehensive mechanisms and clinical trials Relevance to Canine Applications: Current state of senolytic research and clinical applications

14. Bloom et al. (2023) Study Type: Review Article Key Findings: Mechanisms and consequences of endothelial cell senescence; cardiovascular implications Relevance to Canine Applications: Specific mechanisms of cardiovascular senescence relevant to dogs

15. Chen et al. (2022) Study Type: Review Article Key Findings: Senescence mechanisms and targets in the heart; cardiac-specific senescence pathways Relevance to Canine Applications: Heart-specific senescence mechanisms and therapeutic targets

Note: This article is for educational purposes and should not replace professional veterinary advice. Always consult with a qualified veterinarian before implementing any new treatments or supplements for your dog. The field of senolytic research is rapidly evolving, and recommendations may change as new evidence becomes available.